BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Mar 22, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Silenor doxepin regulatory update

FDA approved an NDA from Somaxon for Silenor doxepin to treat insomnia characterized by difficulty with sleep maintenance. Somaxon, which is seeking a commercialization partner in the U.S., plans...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >